Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LIPE | Q05469 | 1/20 | 0.52 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.52 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.52 |
| ▸ | CHRM1 | P11229 | 1/20 | 0.52 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.52 |
| ▸ | HTR2C | P28335 | 2/20 | 0.51 |
| ▸ | P2RY14 | Q15391 | 6/20 | 0.50 |
| ▸ | DRD1 | P21728 | 2/20 | 0.50 |
| ▸ | DRD5 | P21918 | 2/20 | 0.50 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.50 |
| ▸ | ADRA2C | P18825 | 1/20 | 0.50 |
| ▸ | HTR1D | P28221 | 1/20 | 0.50 |
| ▸ | HTR1E | P28566 | 1/20 | 0.50 |
| ▸ | TSPO | P30536 | 1/20 | 0.50 |
| ▸ | ADRA1A | P35348 | 1/20 | 0.50 |
| ▸ | DRD3 | P35462 | 1/20 | 0.50 |
| ▸ | HTR5A | P47898 | 1/20 | 0.50 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.50 |
| ▸ | GAA | P10253 | 1/20 | 0.48 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5535882 | 0.86 | LIPE (0.51) | LIPECHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL1581482 | 0.82 | DRD2 (0.58) | HTR2CNOTUMRBP4 | |
| SCHEMBL2636274 | 0.81 | RAB9A (0.57) | GAAHSD11B1 | |
| SCHEMBL23577524 | 0.81 | GAA (0.50) | CHRM2CHRM5CHRM1CHRM3GAA | |
| SCHEMBL8220312 | 0.81 | LIPE (0.50) | LIPECHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL20568305 | 0.81 | RBP4 (0.42) | LIPECHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL21381864 | 0.81 | HDAC4 (0.47) | LIPECHRM2CHRM5CHRM1CHRM3 | |
| SCHEMBL21381906 | 0.81 | GAA (0.48) | GAATDP1NOTUMTRPV1HSD11B1 | |
| SCHEMBL23859722 | 0.81 | MGLL (0.60) | CHRM2CHRM5CHRM1CHRM3P2RY14 | |
| SCHEMBL23442930 | 0.80 | MAPT (0.47) | LIPECHRM2CHRM5CHRM1CHRM3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7968550-B2 | Substituted N-aryl heterocycles, process for their preparation and their use as medicaments | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2011-06-28 | — | — | US | disclosed |
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | SANOFI-AVENTIS DEUTSCHLAND GMBH (DE) | 2007-09-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070207991-A1 | Substituted N-aryl Heterocycles, Process For Their Preparation and Their Use As Medicaments | CYP11B2, CYP11B1, NQO1 | LIPE 2800/4885CHRM2 2219/4885CHRM5 1938/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.